Recently Featured

BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer

May 21, 2026
Shortly after finalizing its $4.8 billion acquisition of Amicus Therapeutics, BioMarin is moving to consolidate operations by integrating staff at the acquired company’s headquarters in New Jersey. This strategic decision reflects BioMarin’s commitment to streamline its workforce and optimize resources following the significant investment in expanding its portfolio in the rare disease sector. The consolidation…

Understanding Borderline Products: Defining Medicinal Products in Regulatory Context

May 20, 2026
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has clarified its approach to determining whether a product qualifies as a medicinal product, a critical consideration for pharmaceutical companies navigating compliance. This guidance addresses the complexities surrounding borderline products, which may straddle the line between medicines and other categories, such as cosmetics or dietary supplements.…

Arvinas, Pfizer Secure New Partner for Veppanu, Addressing Financial Uncertainties

May 20, 2026
A deal with Rigel Pharmaceuticals has been finalized, bringing clarity to the future of Veppanu, a newly approved breast cancer treatment that utilizes Protac technology. This partnership comes after months of speculation regarding the drug’s financial viability and market positioning. The collaboration with Rigel not only stabilizes Veppanu’s trajectory but also underscores the growing interest…

Isomorphic Labs Secures $2.1 Billion in Series B Funding, Reinforcing AI’s Role in Drug Discovery

May 20, 2026
Isomorphic Labs announced the successful closure of a $2.1 billion Series B funding round, underscoring its pivotal role in the integration of artificial intelligence within drug discovery processes. This significant financial milestone positions Isomorphic as a leader in the biotech sector, particularly notable as it marks the second-largest fundraising effort for a privately held biotech…

Ongoing Cases